We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-3 of 3

FDA approves Novartis’ Zarxio as the first biosimilar in the U.S., clearing the drug for the same indications as Neupogen and giving it a placeholder nonproprietary name
  • Loeb & Loeb LLP
  • USA
  • April 7 2015

The regulator granted a landmark approval to the copycat version of the already approved drug in the U.S., opening up the market to less expensive



Scott S. Liebman
  • Loeb & Loeb LLP